Trivecta has a triple-taper femoral stem to fit a diverse range of patient anatomies, according to a news release. It also has sintered beads for initial and long-term stability, and Hydroxyapatite encourages biological fixation.
The implant will be available in the U.S. starting in the second quarter of 2024.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
